| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 08/29/2002 | WO2002066630A1 Methods of modifying eukaryotic cells |
| 08/29/2002 | WO2002066625A1 Novel gene and uses therefor to modify pasture qualities of crops |
| 08/29/2002 | WO2002066618A1 Rapid production of monoclonal antibodies |
| 08/29/2002 | WO2002066603A2 Chemically defined medium for cultured mammalian cells |
| 08/29/2002 | WO2002066516A2 Antibodies that bind both bcma and taci |
| 08/29/2002 | WO2002066515A1 Generation of monoclonal antibodies to poorly immunogenic antigens expressed or carried by eukaryotic cells, use of monoclonal antibodies for therapeutical, diagnostic or vaccine applications |
| 08/29/2002 | WO2002066514A2 Artificial fusion proteins with reduced immunogenicity |
| 08/29/2002 | WO2002066509A2 Treatment involving dkk-1 or antagonists thereof |
| 08/29/2002 | WO2002066507A2 Histidine phosphatase interacting protein of 120 kd |
| 08/29/2002 | WO2002066494A2 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade |
| 08/29/2002 | WO2002066492A2 Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof |
| 08/29/2002 | WO2002066063A1 Remedies for metabolic bone diseases |
| 08/29/2002 | WO2002066059A2 Agents that specifically block cd28-mediated signaling and uses therefor |
| 08/29/2002 | WO2002066058A1 Modified anti-egfr antibodies with reduced immunogenicity |
| 08/29/2002 | WO2002066057A2 Methods and compositions for preventing and treating neutrophil-mediated diseases |
| 08/29/2002 | WO2002066053A2 Method of treating or preventing disease characterized by cryptococcus neoformans infection |
| 08/29/2002 | WO2002065943A2 Ocular tear growth factor-like protein |
| 08/29/2002 | WO2002050108A3 Immunogenic glycopeptides, screening, preparation and uses |
| 08/29/2002 | WO2002036624A3 Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof |
| 08/29/2002 | WO2002033112A3 Protein-protein interactions in neurodegenerative diseases |
| 08/29/2002 | WO2002022795A3 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 08/29/2002 | WO2002020786A3 Kinase d interacting protein |
| 08/29/2002 | WO2002020723A3 Compositions and methods for targeting peptides in humans in vivo |
| 08/29/2002 | WO2002016409A3 Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
| 08/29/2002 | WO2002010388A3 C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF |
| 08/29/2002 | WO2001096547A3 Human kinases |
| 08/29/2002 | WO2001090157A3 98p7c3: homeodomain protein highly expressed in various cancers |
| 08/29/2002 | WO2001085952A3 Modified inosine 5'-monophosphate dehydrogenase polypeptides and uses thereof |
| 08/29/2002 | WO2001085944A3 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 08/29/2002 | WO2001080888A3 Method for treatment of tumors using photodynamic therapy |
| 08/29/2002 | WO2001077338A3 Human protein kinases and protein kinase-like enzymes |
| 08/29/2002 | WO2001068848A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 08/29/2002 | WO2001061055A3 Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes |
| 08/29/2002 | WO2001007481A9 Antitumor antibodies, proteins, and uses thereof |
| 08/29/2002 | WO2001005427A9 Psca: prostate stem cell antigen and uses thereof |
| 08/29/2002 | WO2001003515A9 Method of obtaining protein isolates and concentrates from colostrum |
| 08/29/2002 | WO2000068382A9 PrP-LIKE GENE |
| 08/29/2002 | WO2000063245A9 Variant of the plasmodium merozoite surface protein (msp-1) and vaccine comprising said variant |
| 08/29/2002 | WO2000061606A9 Novel human voltage-gated potassium channel |
| 08/29/2002 | WO2000056866A9 Akt-3 nucleic acids, polypeptides, and uses thereof |
| 08/29/2002 | WO2000037502A9 Vascular endothelial cell growth factor antagonists and uses thereof |
| 08/29/2002 | WO2000034475A9 Grnf4, a gdnf-related neurotrophic factor |
| 08/29/2002 | WO2000034474A9 Growth factor homolog zvegf3 |
| 08/29/2002 | WO2000034447A9 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 08/29/2002 | WO2000023569A9 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 08/29/2002 | WO1999064055A9 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht4 receptors |
| 08/29/2002 | WO1999057280A9 Neisseria meningitidis antigens and compositions |
| 08/29/2002 | US20020120947 Protein-protein interactions in neurodegenerative disorders |
| 08/29/2002 | US20020120123 Human vascular endothelial growth factor 2 |
| 08/29/2002 | US20020120107 Monoclonal antibody recognizing phosphatidylinositol-3,4,5-triphosphate |
| 08/29/2002 | US20020120106 Peptides of the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107, antibodies specific for the peptides and methods of stimulating immune response; antisense agents |
| 08/29/2002 | US20020120103 17 human secreted proteins |
| 08/29/2002 | US20020119944 Use of Ulip-and/or Ulip2 in the treatment of myelin disorders |
| 08/29/2002 | US20020119943 Novel mammalian gene,bcl-w, belongs to the bcl-2 family of apoptosis-controlling genes |
| 08/29/2002 | US20020119927 Protein-protein interactions in neurodegenerative diseases |
| 08/29/2002 | US20020119926 Inhibitors of IAPP fibril formation and uses thereof |
| 08/29/2002 | US20020119582 Signal enhancement of bispecific antibody-polymer probe for immunoassay use |
| 08/29/2002 | US20020119568 Providing a population of cells having a target cell surface molecule, a culture vessel and magnets, vessel contains a solid surface having attached thereto a ligand for a target cell surface molecule, applying magnetic field |
| 08/29/2002 | US20020119548 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 08/29/2002 | US20020119545 Isolated mammalian nucleic acid molecule encoding a receptor protein tyrosine kinase expressed in primitive hematopcietic cells and not expressed in mature hematopoietic cells |
| 08/29/2002 | US20020119526 Nucleic acids encoding a G-protein coupled receptor involved in sensory transduction |
| 08/29/2002 | US20020119524 Novel molecules of the T129-related protein family and uses thereof |
| 08/29/2002 | US20020119519 Nucleotide sequences coding preferential polyeptide for use in the treatment of cancer, kidney and respiratory disorders |
| 08/29/2002 | US20020119518 Peptide for use in treatment and diagnosis of heart defects |
| 08/29/2002 | US20020119510 Enzymatic polypeptide for use in screening bactericides |
| 08/29/2002 | US20020119504 Antibody or antigen-binding sequences for use in the treatment of inflammatory bowel disease |
| 08/29/2002 | US20020119447 Non-a,non-b,non-c,non-c,non-d,non-e hepatitis reagents and methods for their use |
| 08/29/2002 | US20020119189 Nucleosome-based anti-tumor compositions |
| 08/29/2002 | US20020119158 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 08/29/2002 | US20020119157 For cancer therapy |
| 08/29/2002 | US20020119155 Protein-protein interactions in neurodegenerative diseases |
| 08/29/2002 | US20020119154 For diagnosing diseases associated with somatolactogenic functions in patients |
| 08/29/2002 | US20020119153 Antibody conjugate formulations for selectively inhibiting VEGF |
| 08/29/2002 | US20020119152 Administering to the individual a therapeutically effective amount of an anti-TNF alpha antibody or an antigen binding fragment thereof |
| 08/29/2002 | US20020119151 CD154 blockade therapy for therapeutic protein inhibitor syndrome |
| 08/29/2002 | US20020119150 Administering an effective amount of a CD40:CD154 binding interrupter to primate graft recipient for therapy of rejection of tissue graft |
| 08/29/2002 | US20020119148 ErbB4 antagonists |
| 08/29/2002 | US20020119147 Apparatus for enhancing immune responses in mammals |
| 08/29/2002 | US20020119130 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 08/29/2002 | US20020119096 Fluorination of proteins and peptides for F-18 positron emission tomography |
| 08/29/2002 | CA2439235A1 Methods for immuno-detection of epitopes on molecules and for detection of interactions of molecules via fluorescent dyes |
| 08/29/2002 | CA2438822A1 Novel gene and uses therefor to modify pasture qualities of crops |
| 08/29/2002 | CA2438818A1 Rapid production of monoclonal antibodies |
| 08/29/2002 | CA2438775A1 T cell receptor variants expressed in mesenchymal cells and uses thereof |
| 08/29/2002 | CA2438769A1 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof |
| 08/29/2002 | CA2438682A1 Antibodies that bind both bcma and taci |
| 08/29/2002 | CA2438628A1 Artificial proteins with reduced immunogenicity |
| 08/29/2002 | CA2438513A1 Modified anti-egfr antibodies with reduced immunogenicity |
| 08/29/2002 | CA2438390A1 Methods of modifying eukaryotic cells |
| 08/29/2002 | CA2438371A1 Histidine phosphatase interacting protein of 120 kd |
| 08/29/2002 | CA2438369A1 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade |
| 08/29/2002 | CA2438245A1 Treatment involving dkk-1 or antagonists thereof |
| 08/29/2002 | CA2438235A1 Neurotransmission-associated proteins |
| 08/29/2002 | CA2438148A1 Chemically defined medium for cultured mammalian cells |
| 08/29/2002 | CA2437161A1 Anti-interferon-.alpha. antibodies |
| 08/29/2002 | CA2436516A1 Pg-3 and biallelic markers thereof |
| 08/29/2002 | CA2434652A1 Type 2 cytokine receptor and nucleic acids encoding same |
| 08/28/2002 | EP1234879A2 Human nucleic acid sequences from prostate tumour tissue |
| 08/28/2002 | EP1234574A1 Hair growth stimulant |
| 08/28/2002 | EP1234179A2 Naive screening method |